Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
Langzeitnachbeobachtung und Gesamtüberleben in NRG258, einer randomisierten Phase-III-Studie zu Chemoradiotherapie versus Chemotherapie bei lokal fortgeschrittenem Endometriumkarzinom
Journal of Clinical Oncology · 20.03.2025 · 43 (9) · 1055-1060
DOI: 10.1200/jco.24.01121 ↗Auf einen Blick
In der Phase-III-Studie NRG258 verbesserte Chemoradiotherapie das Gesamtüberleben bei lokal fortgeschrittenem Endometriumkarzinom nicht gegenüber Chemotherapie. Das lokale Rezidiv war zwar seltener, RFS und OS stiegen aber nicht.
Fragestellung
Erhöht Chemoradiotherapie im Vergleich zu Chemotherapie das rezidivfreie Überleben und das Gesamtüberleben bei lokal fortgeschrittenem Endometriumkarzinom?
Methode
Randomisierte Phase-III-Studie; 813 Patient:innen mit FIGO 2009 Stadium III-IVA oder Stadium I/II serösem bzw. klarzelligem UC und positiver Zytologie; medianes Follow-up 112 Monate.
Ergebnisse
813 Patient:innen: 407 C-RT, 406 CT. Medianes OS wurde in beiden Gruppen nicht erreicht. Für Tod: HR 1,05 (95 %-KI 0,82–1,34; P=.72). Kein untersuchter Faktor sagte OS-Benefit durch C-RT voraus.
Schlussfolgerung der Autor:innen
C-RT verringerte die lokale Rezidivrate im Vergleich zu CT, erhöhte aber weder OS noch RFS bei Stadium III/IVA UC.
Kernaussagen
- OS: kein Vorteil für C-RT gegenüber CT
- HR für Tod 1,05 (95 %-KI 0,82–1,34)
- Lokale Rezidive seltener unter C-RT
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.03.2025. Verfasst von Daniela E Matei und 23 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University, Chicago, IL. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
This randomized phase III trial aimed to determine whether treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for four cycles (chemoradiotherapy [C-RT]) increased recurrence-free survival (RFS) and overall survival (OS) when compared with carboplatin and paclitaxel for six cycles (chemotherapy [CT]) in locally advanced endometrial cancer (UC). Previously reported results showed that C-RT did not improve RFS compared with CT. Here we report the final OS analysis. Patients with International Federation of Gynecology and Obstetrics (FIGO) 2009 stage III-IVA UC or stage I/II serous or clear cell UC and positive cytology were enrolled. The primary objective was RFS. Secondary objectives were OS, toxicity, and quality of life. Cumulative probabilities of OS were estimated using the Kaplan-Meier method. Subgroup analyses of treatment effect for FIGO stage, age, race, gross residual disease, histology, lymph-vascular space invasion, and body mass index were performed. In total, 813 patients were randomly assigned (407 C-RT and 406 CT). The median follow-up was 112 months. Median OS was not achieved in either arm. The stratified hazard ratio for death comparing C-RT versus CT was 1.05 (95% CI, 0.82 to 1.34, log-rank two-sided P value = .72). None of the factors analyzed predicted OS benefit from C-RT. Although C-RT reduced the rate of local recurrence compared with CT, it did not increase OS or RFS in stage III/IVA UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Northwestern University, Chicago, IL.
- NRG Oncology Statistical and Data Center, Buffalo, NY.
- University of Kentucky, Lexington, KY.
- Washington University School of Medicine, Siteman Cancer Center, St Louis, MO.
- Stritch School of Medicine Loyola University, Chicago, IL.
- Women and Infants Hospital in Rhode Island/The Warren Alpert Medical School of Brown University, Providence, RI.
ORCID-Profile: Daniela E Matei, Marcus E Randall, David Mutch, William Small, Paul A DiSilvestro, David M O'Malley, Guilherme H Cantuaria, Olivia Lara, Frederick R Ueland, David Warshal, Krishnansu S Tewari, Annie Tan, Matthew A Powell, Joan L Walker, Alessandro D Santin, David S Miller
Förderung
- NCI NIH HHS
Zitieren
APA
Matei, D. E., Enserro, D. M., Randall, M. E., Mutch, D., Small, W., DiSilvestro, P. A., Spirtos, N. M., O'Malley, D. M., Cantuaria, G. H., Michelin, D., Waggoner, S., Shahin, M., Guntupalli, S., Lara, O., Ueland, F. R., Warshal, D., Bonebrake, A., Tewari, K. S., Tan, A., …, & Miller, D. S. (2025). Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. Journal of Clinical Oncology, 43(9), 1055-1060. https://doi.org/10.1200/jco.24.01121
Vancouver
Matei DE, Enserro DM, Randall ME, Mutch D, Small W, DiSilvestro PA, et al. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. Journal of Clinical Oncology. 2025;43(9):1055-1060. doi:10.1200/jco.24.01121
BibTeX
@article{Matei2025,
author = {Matei, Daniela E and Enserro, Danielle M and Randall, Marcus E and Mutch, David and Small, William and DiSilvestro, Paul A and Spirtos, Nick M and O'Malley, David M and Cantuaria, Guilherme H and Michelin, David and Waggoner, Steven and Shahin, Mark and Guntupalli, Saketh and Lara, Olivia and Ueland, Frederick R and Warshal, David and Bonebrake, Albert and Tewari, Krishnansu S and Tan, Annie and Powell, Matthew A and Walker, Joan L and Santin, Alessandro D and Kim, Jong Hyeok and Miller, David S},
title = {Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {9},
pages = {1055--1060},
doi = {10.1200/jco.24.01121}
}
EUVIMED